EHA26: BTK Degrader Durability Reinforced; Earlier-Line Expansion Emerges

Research evidence excerpt

EHA26: BTK Degrader Durability Reinforced; Earlier-Line Expansion Emerges

USA | Biotechnology

Nurix EquityJuneResearch12, 2026

FLASH NOTEEHA26: BTK Degrader Durability Reinforced;

RATING BUYEarlier-Line Expansion Emerges

PRICE $16.98^

At EHA26, NRIX BTK degrader bexobrutideg and comp tacabrutideg delivered

broadly comparable efficacy across R/R and BTKi-naïve CLL/ SLL (ORR PRICE TARGET | % TO PT $45.00 | +165%

~83-85% and ~84-86%, respectively), reinforcing BTK degraders as a credible 52W HIGH-LOW $22.50 - $8.20

next-gen backbone. Differences in follow-up and reporting are not yet clinically FLOAT (%) | ADV MM (USD) 88.9% | 35.51

meaningful, with no clear leader emerging. Differentiation will likely depend on MARKET CAP $1.9B

durability, safety at scale, and pivotal/ combo readouts. TICKER NRIX ^Prior trading day's closing price unless otherwise

noted.

Bottom Line. At EHA26, bexobrutideg and comp tacabrutideg show broadly comparable efficacy

across both relapsed/ refractory and BTKi-naïve settings (ORR ~83-85% in R/R and ~84-86% in

earlier line), reinforcing the emerging BTK degrader class as a credible next-generation backbone.

While nuances exist around follow-up duration and reporting, these differences are not yet

meaningful enough to establish clear clinical separation. Overall, the data suggest both agents are

competitive and potentially superior to current BTKi, with no clear leader emerging, and differentiation

likely to depend on longer-term durability, safety with broader exposure, and performance in pivotal and

combo settings.

Core efficacy metrics remain largely unchanged vs the prior ASH25 update. ORR was ~83%

(N=48; unchanged vs ~83% at ASH25) and mPFS was 22.1 mos (unchanged vs ASH25) in heavily

pretreated r/r CLL/ SLL pts (Chart 1).